NovoCure

NVCR

Market cap $1.42B

Overview Fund Activity

12.69 USD

+0.01

0.08%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

12.80

+0.11

0.87%

1 day

0.08%

5 days

3.59%

1 month

4.96%

3 months

-27.19%

6 months

-35.22%

Year to date

-57.69%

1 year

-29.58%

5 years

-88.36%

10 years

-30.58%

About: NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Employees: 1,488

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

500% more call options, than puts

Call options by funds: $21.2M | Put options by funds: $3.53M

61% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 28

21% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 71

7% more funds holding

Funds holding: 227 [Q1] → 242 (+15) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

1% less capital invested

Capital invested by funds: $1.7B [Q1] → $1.68B (-$14.4M) [Q2]

1.85% less ownership

Funds ownership: 86.6% [Q1] → 84.75% (-1.85%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14.5

14% upside

Avg. target

$26

106% upside

High target

$34

168% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Wells Fargo Larry Biegelsen	$14.5	Equal-Weight Downgraded	25 Jul 2025
Ladenburg Thalmann Kevin DeGeeter	$30	Buy Initiated	8 Jul 2025
Piper Sandler Jason Bednar	$34	Overweight Reiterated	27 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about NVCR published over the past 30 days

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. “With the Ministry of Health, Labour and Welfare approval granted to Optune Lua, we now have a new treatment option available to.

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

NovoCure Limited (NASDAQ:NVCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 3:20 PM EDT Company Participants Ashley Cordova - CEO & Director Conference Call Participants Kelly McCarthy - Morgan Stanley Presentation Kelly McCarthy Good afternoon, everyone, and we appreciate you joining us for a fireside chat with NovoCure. I'm very happy to be joined by CEO, Ashley Cordova.

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

The Motley Fool

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

@coryrenauer Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure.

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

Novocure Announces Upcoming Investor Events

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright 27th Annual Global Investment Conference, September 9, 2025: Ms. Cordova will take part in a fireside chat at 2:00 p.m.

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Spain's Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. “Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few treatment options. We are very pleased Tumor Treating Fields therapy is now available through the Spanish public heal.

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Zacks Investment Research

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for adults with unresectable, locally advanc.

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

NovoCure's Wearable Oncology Edge And Compelling Valuation

NVCR focuses on Tumor Treating Fields wearables for GBM, mesothelioma, and NSCLC. These are its main recurring revenue verticals. So far, its wearables have shown favorable safety profiles, and suggest they should be a net benefit across other oncology niches. NVCR's late‑stage PANOVA‑3 and METIS trials could continue growing their markets. Currently, management is targeting more PMA filings later this year.

NovoCure's Wearable Oncology Edge And Compelling Valuation

Top 3 Health Care Stocks That May Explode In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That May Explode In July

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

NovoCure Limited (NASDAQ:NVCR ) Q2 2025 Earnings Conference Call July 25, 2025 8:00 AM ET Company Participants Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive VP & President of Novocure Oncology Ingrid Goldberg - VP of Investor Relations William F. Doyle - Executive Chairman Conference Call Participants Emily Claudia Bodnar - H.C.

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™